PRESS RELEASE published on 02/28/2023 at 14:30, 1 year 8 months ago FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
PRESS RELEASE published on 02/23/2023 at 14:30, 1 year 8 months ago Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
PRESS RELEASE published on 02/21/2023 at 14:30, 1 year 9 months ago Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 02/09/2023 at 14:30, 1 year 9 months ago Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
PRESS RELEASE published on 02/08/2023 at 14:30, 1 year 9 months ago Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
PRESS RELEASE published on 02/01/2023 at 15:45, 1 year 9 months ago Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
PRESS RELEASE published on 02/01/2023 at 14:30, 1 year 9 months ago Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling
PRESS RELEASE published on 01/30/2023 at 14:30, 1 year 9 months ago Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
PRESS RELEASE published on 01/27/2023 at 22:15, 1 year 9 months ago Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRESS RELEASE published on 01/26/2023 at 14:30, 1 year 9 months ago Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Published on 11/21/2024 at 14:30, 32 minutes ago Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Published on 11/21/2024 at 14:30, 32 minutes ago Sarama Announces Equity Placement of Up to A$2M and Issue of Equity for Debt
Published on 11/21/2024 at 14:15, 47 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 1 hour 2 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 1 hour 2 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:16, 46 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 47 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 1 hour 2 minutes ago Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:41, 1 hour 21 minutes ago Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Published on 11/21/2024 at 06:58, 8 hours 4 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 4 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 4 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 18 hours 55 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 19 hours 42 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
